Advertisement
U.S. markets close in 3 hours 1 minute
  • S&P 500

    5,251.54
    +3.05 (+0.06%)
     
  • Dow 30

    39,776.78
    +16.70 (+0.04%)
     
  • Nasdaq

    16,380.86
    -18.67 (-0.11%)
     
  • Russell 2000

    2,128.95
    +14.60 (+0.69%)
     
  • Crude Oil

    82.73
    +1.38 (+1.70%)
     
  • Gold

    2,242.30
    +29.60 (+1.34%)
     
  • Silver

    24.98
    +0.23 (+0.92%)
     
  • EUR/USD

    1.0801
    -0.0028 (-0.26%)
     
  • 10-Yr Bond

    4.1930
    -0.0030 (-0.07%)
     
  • GBP/USD

    1.2634
    -0.0004 (-0.03%)
     
  • USD/JPY

    151.3370
    +0.0910 (+0.06%)
     
  • Bitcoin USD

    70,607.24
    +1,405.36 (+2.03%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Abcam signs licensing deal with Roche; shares rise

(Reuters) - British biotechnology firm Abcam Plc (ABCA.L) said on Monday it signed a deal with Roche Holding AG (ROG.S) to get rights to a portfolio of the Swiss drugmaker's research products in its life science division.

The Cambridge-based antibody maker said it would obtain the exclusive rights to brand and market a portfolio of 760 products that are for research use only (RUO) from Roche's U.S.-based unit Spring Bioscience Corp.

Roche will retain the antibody development capabilities and rights pertaining to the Spring Portfolio for internal research, companion diagnostic and IVD uses.

Abcam said it was also granted RUO rights for all future products developed by Spring that Roche requests to be commercialised for an initial period of 10 years.

Shares of Abcam were up about 1.2 percent at 0851 GMT (9.51 a.m. BST).

(Reporting By Justin George Varghese in Bengaluru; Editing by Gopakumar Warrier)

Advertisement